Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Announces $0.88 Quarterly Dividend

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced a quarterly dividend on Monday, February 17th,RTT News reports. Investors of record on Thursday, February 20th will be given a dividend of 0.88 per share by the biopharmaceutical company on Thursday, March 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date is Thursday, February 20th.

Regeneron Pharmaceuticals Stock Down 0.1 %

NASDAQ REGN opened at $673.60 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 4.46. The company’s 50 day simple moving average is $704.64 and its 200 day simple moving average is $891.91. Regeneron Pharmaceuticals has a 12 month low of $642.00 and a 12 month high of $1,211.20. The company has a market capitalization of $74.02 billion, a P/E ratio of 17.60, a PEG ratio of 2.38 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the firm earned $11.86 EPS. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals will post 36.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

REGN has been the topic of a number of research reports. Wells Fargo & Company dropped their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Bank of America restated an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Bernstein Bank cut their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Citigroup cut their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Finally, Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.